Published in J Neuroinflammation on May 29, 2012
Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? J Neuroinflammation (2014) 1.41
IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology. J Neuroinflammation (2014) 0.88
Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol (2014) 0.87
Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimers Res Ther (2014) 0.85
Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes. Neurol Neuroimmunol Neuroinflamm (2016) 0.84
Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation (2013) 0.83
Anti-inflammatory and anti-amyloidogenic effects of a small molecule, 2,4-bis(p-hydroxyphenyl)-2-butenal in Tg2576 Alzheimer's disease mice model. J Neuroinflammation (2013) 0.81
Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia. J Neuroinflammation (2013) 0.81
Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. J Neuroinflammation (2012) 0.80
Immunomodulation and AD--down but not out. J Clin Immunol (2014) 0.80
Association of CD33 polymorphism rs3865444 with Alzheimer's disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging (2014) 0.80
Intravenous immunoglobulin for Alzheimer's disease. Clin Exp Immunol (2014) 0.79
Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol (2014) 0.79
Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β. Sci Rep (2016) 0.78
Susceptibility to focal and global brain ischemia of Alzheimer mice displaying aβ deposits: effect of immunoglobulin. Aging Dis (2014) 0.78
Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide. PLoS One (2012) 0.77
Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro. PLoS One (2013) 0.77
Compound danshen tablet ameliorated aβ25-35-induced spatial memory impairment in mice via rescuing imbalance between cytokines and neurotrophins. BMC Complement Altern Med (2014) 0.77
Deletion of Nuclear Factor kappa B p50 Subunit Decreases Inflammatory Response and Mildly Protects Neurons from Transient Forebrain Ischemia-induced Damage. Aging Dis (2015) 0.75
Candidate SNP Markers of Familial and Sporadic Alzheimer's Diseases Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters. Front Aging Neurosci (2017) 0.75
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci (2007) 11.11
Inflammatory blockade restores adult hippocampal neurogenesis. Science (2003) 10.14
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Physiology of microglia. Physiol Rev (2011) 6.99
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Irradiation induces neural precursor-cell dysfunction. Nat Med (2002) 5.46
Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A (2003) 5.09
Alzheimer's disease: clinical trials and drug development. Lancet Neurol (2010) 4.65
Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci (2006) 4.30
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci (2008) 3.90
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 3.80
Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci (2005) 3.77
IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A (2008) 3.19
Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience (1994) 3.10
Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol (2008) 3.05
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis (2006) 2.96
Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci (2001) 2.85
Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci (2009) 2.85
Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience (2008) 2.84
Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol (2003) 2.50
The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond) (2003) 2.49
Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci (2002) 2.45
Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry (2007) 2.38
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (2008) 2.24
Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis (2005) 2.16
Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 2.12
Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci (2001) 1.99
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci (2006) 1.91
Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur J Neurosci (2006) 1.88
Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke (2006) 1.73
Inflammation: a new candidate in modulating adult neurogenesis. J Neurosci Res (2008) 1.55
IVIG treatment and prognosis in Guillain-Barré syndrome. J Clin Immunol (2010) 1.46
The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol (2010) 1.43
Shortage of human intravenous immunoglobulin--reasons and possible solutions. Nat Clin Pract Neurol (2007) 1.35
Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J (2006) 1.32
Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology (2011) 1.31
Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci (2011) 1.26
Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.24
CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice. J Neurosci (2011) 1.22
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.18
Cytokine regulation of neuronal differentiation of hippocampal progenitor cells. Nature (1993) 1.18
Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci (2005) 1.15
IL-4 attenuates the neuroinflammation induced by amyloid-beta in vivo and in vitro. J Neurochem (2007) 1.14
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 1.12
Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr Alzheimer Res (2009) 1.09
Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology (2006) 1.09
Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. J Neurosci (2009) 1.05
Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease. Acta Neuropathol (1991) 1.02
Human intravenous immunoglobulin modulates monokine production in vitro. Immunology (1990) 1.02
Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res (2006) 1.01
Proinflammatory cytokines differentially influence adult hippocampal cell proliferation depending upon the route and chronicity of administration. Neuropsychiatr Dis Treat (2009) 1.00
Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry (2008) 0.96
Reduced neurogenesis in the rat hippocampus following high fructose consumption. Regul Pept (2010) 0.96
In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol (1995) 0.95
Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology (2000) 0.93
The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets (2009) 0.92
Neurogenesis in the adult brain: implications for Alzheimer's disease. CNS Neurol Disord Drug Targets (2007) 0.92
Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol (1996) 0.92
The role of microglial cell subsets in Alzheimer's disease. Curr Alzheimer Res (2011) 0.90
Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci (2007) 0.89
Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol (2010) 0.88
Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol (1994) 0.88
I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology (1999) 0.86
NF-κB1 inhibits TLR-induced IFN-β production in macrophages through TPL-2-dependent ERK activation. J Immunol (2011) 0.85
Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. J Clin Immunol (1993) 0.85
Vaccines: chasing the dream. Nature (2011) 0.85
Rapid cerebral amyloid binding by Aβ antibodies infused into β-amyloid precursor protein transgenic mice. Biol Psychiatry (2010) 0.81
Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatr Allergy Immunol (2006) 0.80
Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease. Drugs Today (Barc) (2007) 0.78
Intravenous immunoglobulin prevents release of proinflammatory cytokines in human monocytic cells stimulated with procalcitonin. Inflamm Res (2012) 0.77
Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci (2009) 2.33
Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis (2008) 2.26
Neurocognitive aging: prior memories hinder new hippocampal encoding. Trends Neurosci (2006) 2.20
Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis (2005) 2.16
Age-associated alterations of hippocampal place cells are subregion specific. J Neurosci (2005) 1.82
Stroke research priorities for the next decade--A representative view of the European scientific community. Cerebrovasc Dis (2006) 1.75
Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett (2008) 1.75
Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging (2006) 1.74
Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci (2004) 1.74
Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain (2002) 1.71
Visual presentation of novel objects and new spatial arrangements of objects differentially activates the medial temporal lobe subareas in humans. Eur J Neurosci (2004) 1.63
Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke (2004) 1.58
Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease. J Neurochem (2013) 1.51
Protein disulfide isomerase in ALS mouse glia links protein misfolding with NADPH oxidase-catalyzed superoxide production. Hum Mol Genet (2012) 1.49
Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia (2002) 1.49
Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis (2003) 1.48
Orexin loss in Huntington's disease. Hum Mol Genet (2004) 1.33
Nrf2 regulates antioxidant gene expression evoked by oxidized phospholipids in endothelial cells and murine arteries in vivo. Circ Res (2008) 1.32
Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.31
Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med (2006) 1.29
Flexible polyimide microelectrode array for in vivo recordings and current source density analysis. Biosens Bioelectron (2006) 1.28
Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci (2007) 1.28
Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation. Brain Res Brain Res Rev (2005) 1.26
Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia (2008) 1.23
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.18
Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2004) 1.17
Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis (2004) 1.17
Cognitive aging and the hippocampus: how old rats represent new environments. J Neurosci (2004) 1.17
Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. Eur J Neurosci (2006) 1.15
Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiol Aging (2007) 1.15
Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis (2005) 1.15
Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab (2005) 1.14
Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) (2005) 1.14
Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci (2008) 1.11
Encoding of novel picture pairs activates the perirhinal cortex: an fMRI study. Hippocampus (2003) 1.10
Pyrrolidine dithiocarbamate inhibits translocation of nuclear factor kappa-B in neurons and protects against brain ischaemia with a wide therapeutic time window. J Neurochem (2004) 1.10
Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain (2011) 1.10
Hypothermia in mice tested in Morris water maze. Behav Brain Res (2003) 1.09
Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res (2010) 1.08
WNT signaling in activated microglia is proinflammatory. Glia (2010) 1.07
Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. J Biol Chem (2008) 1.06
Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology (2008) 1.06
The role and therapeutic potential of monocytic cells in Alzheimer's disease. Glia (2010) 1.04
Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A (2002) 1.04
Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis (2008) 1.03
Role of alpha-synuclein in synaptic glutamate release. Neurobiol Dis (2007) 1.02
Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging (2011) 1.01
Individual differences in neurocognitive aging of the medial temporal lobe. Age (Dordr) (2006) 1.01
Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging (2005) 0.99
Distal occlusion of the middle cerebral artery in mice: are we ready to assess long-term functional outcome? Transl Stroke Res (2013) 0.98
Effects of ovariectomy and estrogen treatment on learning and hippocampal neurotransmitters in mice. Horm Behav (2002) 0.97
Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis (2002) 0.97
The microglia-activating potential of thrombin: the protease is not involved in the induction of proinflammatory cytokines and chemokines. J Biol Chem (2004) 0.97
Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J Neuroinflammation (2011) 0.96
Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia (2011) 0.96
Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis (2002) 0.95
Cholinergic system regulation of spatial representation by the hippocampus. Hippocampus (2002) 0.95
Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res (2011) 0.95
Decreased reuptake of dopamine in the dorsal striatum in the absence of α-synuclein. Brain Res (2011) 0.95
Glycosylation changes in Alzheimer's disease as revealed by a proteomic approach. Neurosci Lett (2004) 0.94
Discriminating accuracy of medial temporal lobe volumetry and fMRI in mild cognitive impairment. Hippocampus (2009) 0.94
beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proc Natl Acad Sci U S A (2006) 0.94
Estrogen treatment alleviates NMDA-antagonist induced hippocampal LTP blockade and cognitive deficits in ovariectomized mice. Neurobiol Learn Mem (2003) 0.92
Gender-Specific Mechanism of Synaptic Impairment and Its Prevention by GCSF in a Mouse Model of ALS. Front Cell Neurosci (2011) 0.92
Antioxidant pyrrolidine dithiocarbamate activates Akt-GSK signaling and is neuroprotective in neonatal hypoxia-ischemia. Free Radic Biol Med (2006) 0.92
Effects of long-term ovariectomy and estrogen treatment on maze learning in aged mice. Exp Gerontol (2004) 0.92
Mobile phone radiation and the developing brain: behavioral and morphological effects in juvenile rats. Radiat Res (2007) 0.92
Lack of collagen XV impairs peripheral nerve maturation and, when combined with laminin-411 deficiency, leads to basement membrane abnormalities and sensorimotor dysfunction. J Neurosci (2010) 0.91
Neurochemical mapping of the human hippocampus reveals perisynaptic matrix around functional synapses in Alzheimer's disease. Acta Neuropathol (2012) 0.90
Aspirin provides cyclin-dependent kinase 5-dependent protection against subsequent hypoxia/reoxygenation damage in culture. J Neurochem (2002) 0.90
Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res (2007) 0.90
Nrf2 regulates neurogenesis and protects neural progenitor cells against Aβ toxicity. Stem Cells (2014) 0.90
Aspirin inhibits p44/42 mitogen-activated protein kinase and is protective against hypoxia/reoxygenation neuronal damage. Stroke (2003) 0.89
Noradrenaline overflow in mouse dentate gyrus following locus coeruleus and natural stimulation: real-time monitoring by in vivo voltammetry. J Neurochem (2005) 0.89
Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol Pharmacol (2006) 0.89
Increased expression of Abeta degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neurosci Lett (2008) 0.88
Mutant SOD1 from spinal cord of G93A rats is destabilized and binds to inner mitochondrial membrane. Neurobiol Dis (2008) 0.88
Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. J Neurochem (2006) 0.88
Distinct and overlapping fMRI activation networks for processing of novel identities and locations of objects. Eur J Neurosci (2005) 0.87
Neurotrophins and dementia--keeping in touch. Neuron (2006) 0.87
From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J Chromatogr A (2011) 0.87
Fabrication and testing of polyimide-based microelectrode arrays for cortical mapping of evoked potentials. Biosens Bioelectron (2009) 0.87
Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice. Neurobiol Dis (2010) 0.87
Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications. Int J Alzheimers Dis (2011) 0.86
Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J Cell Mol Med (2012) 0.86